Some people grow and sell a plant called marijuana. It is not allowed by the big boss of the country, but many states let people use it. A lot of people work in this job, about 440,000. Read from source...

1. The title is misleading and sensationalized. It does not provide any specific or accurate numbers for how many Americans work in the legal cannabis industry in 2024. Instead, it uses a date that is two years ahead to attract attention and create urgency. A better title would be something like "The Current State of Employment in the Legal Cannabis Industry" or "Projected Growth of Jobs in the Legal Can

Based on the article "How Many Americans Work In The Legal Cannabis Industry In 2024?", I have analyzed the current state of the legal cannabis industry in the United States and identified some potential investment opportunities for interested parties. Please note that these recommendations are not guaranteed and involve certain risks, as the regulatory environment and market conditions may change over time.

1. Canopy Growth Corp (CGC) - Canopy is one of the largest and most diversified cannabis companies in the world, with operations in several countries and a strong brand portfolio. The company has a long-term partnership with Constellation Brands (STZ), a major alcohol beverage producer, which provides financial and strategic support for Canopy's expansion plans. Canopy is also developing a range of cannabinoid-based products, such as edibles, beverages, and vaporizers, to capitalize on the growing demand for these formats. The main risk factor for Canopy is the regulatory uncertainty in the US market, where the company has not yet entered. However, with the potential legalization of recreational cannabis at the federal level, Canopy could become a major player in the US market and boost its valuation. As of May 6, 2024, CGC is trading at $31.5 per share, with a market capitalization of $8.9 billion. I recommend buying CGC for long-term growth, as it has a strong competitive position, a loyal customer base, and a visionary management team.

2. Curaleaf Holdings (CURA) - Curaleaf is one of the largest vertically integrated cannabis operators in the US, with presence in 17 states and over 100 dispensaries. The company has a diversified product portfolio, including flower, concentrates, edibles, topicals, and vaporizers. Curaleef also offers wholesale and branded products through its subsidiary Select, which is one of the leading cannabis brands in the US. The main risk factor for Curaleaf is the intense competition in the US market, where there are many other players fighting for market share. However, Curaleaf has a proven track record of delivering strong growth and profitability, as well as acquiring strategic assets to expand its footprint and scale. As of May 6, 2024, CURA is trading at $5.8 per share, with a market capitalization of $1.9 billion. I recommend buying CURA for short-term gains, as it has strong fundamentals, a robust cash flow generation, and a potential upside from further legal